Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Alzheimer's Disease

  Free Subscription

Articles published in Alzheimers Dement

Retrieve available abstracts of 405 articles:
HTML format

Single Articles

    November 2022
  1. FERRELL PB, Fillit H, Neumann PJ, Wall JK, et al
    Toward comprehensive value assessment for Alzheimer's disease innovations.
    Alzheimers Dement. 2022 Nov 25. doi: 10.1002/alz.12874.
    PubMed     Abstract available

  2. DOHERTY JM, Murphy SA, Bayat S, Wisch JK, et al
    Adverse driving behaviors increase over time as a function of preclinical Alzheimer's disease biomarkers.
    Alzheimers Dement. 2022 Nov 23. doi: 10.1002/alz.12852.
    PubMed     Abstract available

  3. CAREY A, Fossati S
    Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer's disease and dementia: New evidence, potential therapeutic strategies, and biomarkers.
    Alzheimers Dement. 2022 Nov 19. doi: 10.1002/alz.12871.
    PubMed     Abstract available

  4. KARPOUZIAN-ROGERS T, Ho E, Novack M, Chinkers M, et al
    Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts.
    Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12816.
    PubMed     Abstract available

  5. GOLDHARDT O, Freiberger R, Dreyer T, Wilner L, et al
    Herpes simplex virus alters Alzheimer's disease biomarkers - A hypothesis paper.
    Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12834.
    PubMed     Abstract available

  6. HUANG J, Stein TD, Wang Y, Ang TFA, et al
    Blood levels of MCP-1 modulate the genetic risks of Alzheimer's disease mediated by HLA-DRB1 and APOE for Alzheimer's disease.
    Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12851.
    PubMed     Abstract available

  7. POLSINELLI AJ, Logan PE, Lane KA, Manchella MK, et al
    APOE epsilon4 carrier status and sex differentiate rates of cognitive decline in early- and late-onset Alzheimer's disease.
    Alzheimers Dement. 2022 Nov 17. doi: 10.1002/alz.12831.
    PubMed     Abstract available

  8. PANG M, Zhu L, Gabelle A, Gafson AR, et al
    Toward the end of a controversy on the effect of reduction in brain amyloid levels on change in cognitive and functional decline in Alzheimer's disease-Reply to a letter.
    Alzheimers Dement. 2022 Nov 16. doi: 10.1002/alz.12864.

  9. REIMAN EM, Pruzin JJ, Rios-Romenets S, Brown C, et al
    A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.
    Alzheimers Dement. 2022 Nov 14. doi: 10.1002/alz.12843.
    PubMed     Abstract available

  10. MINDT MR, Okonkwo O, Weiner MW, Veitch DP, et al
    Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations.
    Alzheimers Dement. 2022 Nov 13. doi: 10.1002/alz.12823.
    PubMed     Abstract available

  11. CHEN XQ, Zuo X, Becker A, Head E, et al
    Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose.
    Alzheimers Dement. 2022 Nov 12. doi: 10.1002/alz.12835.
    PubMed     Abstract available

  12. HSHIEH TT, Gou RY, Jones RN, Leslie DL, et al
    One-year Medicare costs associated with delirium in older hospitalized patients with and without Alzheimer's disease dementia and related disorders.
    Alzheimers Dement. 2022 Nov 10. doi: 10.1002/alz.12826.
    PubMed     Abstract available

  13. HUANG X, Li Y, Fowler C, Doecke JD, et al
    Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease.
    Alzheimers Dement. 2022 Nov 9. doi: 10.1002/alz.12813.
    PubMed     Abstract available

  14. WU R, Tripathy S, Menon V, Yu L, et al
    Fragmentation of rest periods, astrocyte activation, and cognitive decline in older adults with and without Alzheimer's disease.
    Alzheimers Dement. 2022 Nov 6. doi: 10.1002/alz.12817.
    PubMed     Abstract available

  15. ZHANG P, Hou Y, Tu W, Campbell N, et al
    Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans.
    Alzheimers Dement. 2022 Nov 4. doi: 10.1002/alz.12819.
    PubMed     Abstract available

  16. Alzheimer's Association takes on leadership role in landmark Alzheimer's biomarker study.
    Alzheimers Dement. 2022 Nov 4. doi: 10.1002/alz.12873.

  17. KYLE S, Youran T, Thomas W, Liuhua S, et al
    The effect of race and co-morbidities on Alzheimer's disease based on Medicare data.
    Alzheimers Dement. 2022 Nov 3. doi: 10.1002/alz.12838.
    PubMed     Abstract available

  18. GILLIS C, Montenigro P, Nejati M, Maserejian N, et al
    Estimating prevalence of early Alzheimer's disease in the United States, accounting for racial and ethnic diversity.
    Alzheimers Dement. 2022 Nov 2. doi: 10.1002/alz.12822.
    PubMed     Abstract available

  19. Improving community health-care systems' early detection of cognitive decline and dementia.
    Alzheimers Dement. 2022;18:2375-2381.
    PubMed     Abstract available

  20. TEMP AGM, Ly A, van Doorn J, Wagenmakers EJ, et al
    A Bayesian perspective on Biogen's aducanumab trial.
    Alzheimers Dement. 2022;18:2341-2351.
    PubMed     Abstract available

  21. LECCA D, Jung YJ, Scerba MT, Hwang I, et al
    Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.
    Alzheimers Dement. 2022;18:2327-2340.
    PubMed     Abstract available

  22. HEGAZY SH, Thomassen JQ, Rasmussen IJ, Nordestgaard BG, et al
    C-reactive protein levels and risk of dementia-Observational and genetic studies of 111,242 individuals from the general population.
    Alzheimers Dement. 2022;18:2262-2271.
    PubMed     Abstract available

  23. BHASIN H, Agrawal RK
    Triploid genetic algorithm for convolutional neural network-based diagnosis of mild cognitive impairment.
    Alzheimers Dement. 2022;18:2283-2291.
    PubMed     Abstract available

  24. KULLER LH, Snitz BE, Hughes TM, Chang Y, et al
    Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90.
    Alzheimers Dement. 2022;18:2176-2187.
    PubMed     Abstract available

  25. PADOVANI A, Canale A, Schiavon L, Masciocchi S, et al
    Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis.
    Alzheimers Dement. 2022;18:2167-2175.
    PubMed     Abstract available

  26. BELLEVILLE S, Cloutier S, Mellah S, Willis S, et al
    Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia.
    Alzheimers Dement. 2022;18:2140-2150.
    PubMed     Abstract available

    October 2022
  27. HANDELS RLH, Green C, Gustavsson A, Herring WL, et al
    Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge.
    Alzheimers Dement. 2022 Oct 25. doi: 10.1002/alz.12811.
    PubMed     Abstract available

  28. NOVOTNY BC, Fernandez MV, Wang C, Budde JP, et al
    Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer's disease brains.
    Alzheimers Dement. 2022 Oct 17. doi: 10.1002/alz.12800.
    PubMed     Abstract available

  29. NILSSON J, Cousins KAQ, Gobom J, Portelius E, et al
    Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders.
    Alzheimers Dement. 2022 Oct 14. doi: 10.1002/alz.12809.
    PubMed     Abstract available

  30. AAIC((R)) 2022: The promise of Alzheimer's research.
    Alzheimers Dement. 2022 Oct 12. doi: 10.1002/alz.12829.

  31. HARERIMANA NV, Paliwali D, Romero-Molina C, Bennett DA, et al
    The role of mitochondrial genome abundance in Alzheimer's disease.
    Alzheimers Dement. 2022 Oct 12. doi: 10.1002/alz.12812.
    PubMed     Abstract available

  32. LIEBERMAN OJ, Lee S, Zabinski J
    Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium.
    Alzheimers Dement. 2022 Oct 11. doi: 10.1002/alz.12807.
    PubMed     Abstract available

  33. WEINER MW, Veitch DP, Miller MJ, Aisen PS, et al
    Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4.
    Alzheimers Dement. 2022 Oct 9. doi: 10.1002/alz.12797.
    PubMed     Abstract available

  34. STEPHAN BCM, Gaughan DM, Edland S, Gudnason V, et al
    Mid- and later-life risk factors for predicting neuropathological brain changes associated with Alzheimer's and vascular dementia: The Honolulu Asia Aging Study and the Age, Gene/Environment Susceptibility-Reykjavik Study.
    Alzheimers Dement. 2022 Oct 4. doi: 10.1002/alz.12762.
    PubMed     Abstract available

  35. NUYTEMANS K, Lipkin Vasquez M, Wang L, Van Booven D, et al
    Identifying differential regulatory control of APOE varepsilon4 on African versus European haplotypes as potential therapeutic targets.
    Alzheimers Dement. 2022;18:1930-1942.
    PubMed     Abstract available

  36. CORNELL PY, Zhang W, Smith L, Rahman M, et al
    Memory care reduces nursing home admissions among assisted-living residents with dementia.
    Alzheimers Dement. 2022;18:1880-1888.
    PubMed     Abstract available

  37. MARRIOTT RJ, Murray K, Flicker L, Hankey GJ, et al
    Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: The UK Biobank prospective cohort study.
    Alzheimers Dement. 2022;18:1907-1918.
    PubMed     Abstract available

  38. PINK A, Krell-Roesch J, Syrjanen JA, Vassilaki M, et al
    A longitudinal investigation of Abeta, anxiety, depression, and mild cognitive impairment.
    Alzheimers Dement. 2022;18:1824-1831.
    PubMed     Abstract available

  39. JANSSEN O, Jansen WJ, Vos SJB, Boada M, et al
    Characteristics of subjective cognitive decline associated with amyloid positivity.
    Alzheimers Dement. 2022;18:1832-1845.
    PubMed     Abstract available

  40. SCHLIEP KC, Ju S, Foster NL, Smith KR, et al
    How good are medical and death records for identifying dementia?
    Alzheimers Dement. 2022;18:1812-1823.
    PubMed     Abstract available

  41. GAO Y, Felsky D, Reyes-Dumeyer D, Sariya S, et al
    Integration of GWAS and brain transcriptomic analyses in a multiethnic sample of 35,245 older adults identifies DCDC2 gene as predictor of episodic memory maintenance.
    Alzheimers Dement. 2022;18:1797-1811.
    PubMed     Abstract available

    September 2022
  42. HARTZ SM, Mozersky J, Schindler SE, Linnenbringer E, et al
    A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementia.
    Alzheimers Dement. 2022 Sep 30. doi: 10.1002/alz.12781.
    PubMed     Abstract available

  43. SCHAEVERBEKE J, Tome SO, Ronisz A, Ospitalieri S, et al
    Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes.
    Alzheimers Dement. 2022 Sep 28. doi: 10.1002/alz.12794.
    PubMed     Abstract available

  44. KATABATHULA S, Davis PB, Xu R
    Comorbidity-driven multi-modal subtype analysis in mild cognitive impairment of Alzheimer's disease.
    Alzheimers Dement. 2022 Sep 27. doi: 10.1002/alz.12792.
    PubMed     Abstract available

    Alzheimer's disease as an innate autoimmune disease (AD(2) ): A new molecular paradigm.
    Alzheimers Dement. 2022 Sep 27. doi: 10.1002/alz.12789.
    PubMed     Abstract available

  46. LIU KY, Thambisetty M, Howard R
    How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?
    Alzheimers Dement. 2022 Sep 26. doi: 10.1002/alz.12788.
    PubMed     Abstract available

  47. PICHET BINETTE A, Janelidze S, Cullen N, Dage JL, et al
    Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance.
    Alzheimers Dement. 2022 Sep 24. doi: 10.1002/alz.12787.
    PubMed     Abstract available

  48. VETELEANU A, Pape S, Davies K, Kodosaki E, et al
    Complement dysregulation and Alzheimer's disease in Down syndrome.
    Alzheimers Dement. 2022 Sep 23. doi: 10.1002/alz.12799.
    PubMed     Abstract available

  49. YIN L, Zhou J, Li T, Wang X, et al
    Inhibition of the dopamine transporter promotes lysosome biogenesis and ameliorates Alzheimer's disease-like symptoms in mice.
    Alzheimers Dement. 2022 Sep 21. doi: 10.1002/alz.12776.
    PubMed     Abstract available

  50. DEPYPERE H, Vergallo A, Lemercier P, Lista S, et al
    Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease.
    Alzheimers Dement. 2022 Sep 15. doi: 10.1002/alz.12759.
    PubMed     Abstract available

  51. Alzheimer's Association launches ALZ-NET: A long-term data collection and sharing network for new treatments.
    Alzheimers Dement. 2022 Sep 12. doi: 10.1002/alz.12782.

  52. JUTTEN RJ, Papp KV, Hendrix S, Ellison N, et al
    Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.
    Alzheimers Dement. 2022 Sep 10. doi: 10.1002/alz.12773.
    PubMed     Abstract available

  53. MATTKE S, Correa Dos Santos Filho O, Hanson M, Mateus EF, et al
    Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer's disease treatment.
    Alzheimers Dement. 2022 Sep 5. doi: 10.1002/alz.12778.
    PubMed     Abstract available

  54. SKILLBACK T, Blennow K, Zetterberg H, Skoog J, et al
    Slowing gait speed precedes cognitive decline by several years.
    Alzheimers Dement. 2022;18:1667-1676.
    PubMed     Abstract available

    August 2022
  55. JIANG L, Li JC, Tang BS, Guo JF, et al
    Lack of bidirectional association between age-related macular degeneration and Alzheimer's disease: A Mendelian randomization study.
    Alzheimers Dement. 2022 Aug 25. doi: 10.1002/alz.12775.
    PubMed     Abstract available

  56. LUTZ MW, Khachaturian AS, Zetterberg H, Blennow K, et al
    Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide.
    Alzheimers Dement. 2022 Aug 25. doi: 10.1002/alz.12772.

  57. FRIKKE-SCHMIDT R, Hegazy SH, Rasmussen IJ, Nordestgaard BG, et al
    Observational and genetic studies of C-reactive protein levels and risk of Alzheimer's disease.
    Alzheimers Dement. 2022 Aug 21. doi: 10.1002/alz.12742.

  58. RAFII MS, Sperling RA, Donohue MC, Zhou J, et al
    The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
    Alzheimers Dement. 2022 Aug 15. doi: 10.1002/alz.12748.
    PubMed     Abstract available

  59. PALMQVIST S, Stomrud E, Cullen N, Janelidze S, et al
    An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
    Alzheimers Dement. 2022 Aug 11. doi: 10.1002/alz.12751.
    PubMed     Abstract available

  60. LANGBAUM JB, Zissimopoulos J, Au R, Bose N, et al
    Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
    Alzheimers Dement. 2022 Aug 10. doi: 10.1002/alz.12737.
    PubMed     Abstract available

  61. OLCHANSKI N, Daly AT, Zhu Y, Breslau R, et al
    Alzheimer's disease medication use and adherence patterns by race and ethnicity.
    Alzheimers Dement. 2022 Aug 8. doi: 10.1002/alz.12753.
    PubMed     Abstract available

  62. SCHINDLER SE, Li Y, Li M, Despotis A, et al
    Using Alzheimer's disease blood tests to accelerate clinical trial enrollment.
    Alzheimers Dement. 2022 Aug 7. doi: 10.1002/alz.12754.
    PubMed     Abstract available

  63. WANG J, Guo C, Meng Z, Zwan MD, et al
    Testing the link between isoaspartate and Alzheimer's disease etiology.
    Alzheimers Dement. 2022 Aug 4. doi: 10.1002/alz.12735.
    PubMed     Abstract available

  64. MOLONEY CM, Labuzan SA, Crook JE, Siddiqui H, et al
    Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain.
    Alzheimers Dement. 2022 Aug 3. doi: 10.1002/alz.12749.
    PubMed     Abstract available

  65. PETERSEN RC, Graf A, Carrillo MC, Weber CJ, et al
    Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpoints.
    Alzheimers Dement. 2022;18:1586.

    The comprehensive, customized, cost-effective approach (CCCAP) to prevention of dementia.
    Alzheimers Dement. 2022;18:1565-1568.
    PubMed     Abstract available

  67. LENNON JC, Aita SL, Bene VAD, Rhoads T, et al
    Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation.
    Alzheimers Dement. 2022;18:1461-1471.
    PubMed     Abstract available

  68. PERLUIGI M, Picca A, Montanari E, Calvani R, et al
    Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles.
    Alzheimers Dement. 2022;18:1498-1510.
    PubMed     Abstract available

  69. PAJEWSKI NM, Elahi FM, Tamura MK, Hinman JD, et al
    Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Alzheimers Dement. 2022;18:1472-1483.
    PubMed     Abstract available

    July 2022
  70. HANSSON O, Edelmayer RM, Boxer AL, Carrillo MC, et al
    The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 31. doi: 10.1002/alz.12756.
    PubMed     Abstract available

    Risk association between midlife lipid and glucose levels and future Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 28. doi: 10.1002/alz.12738.

  72. LOZUPONE M, Imbimbo BP, Balducci C, Lo Vecchio F, et al
    Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
    Alzheimers Dement. 2022 Jul 28. doi: 10.1002/alz.12728.
    PubMed     Abstract available

  73. MAHAPATRA G, Gao Z, Bateman JR 3rd, Lockhart SN, et al
    Blood-based bioenergetic profiling reveals differences in mitochondrial function associated with cognitive performance and Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 23. doi: 10.1002/alz.12731.
    PubMed     Abstract available

  74. BEYER L, Stocker H, Rujescu D, Holleczek B, et al
    Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.
    Alzheimers Dement. 2022 Jul 19. doi: 10.1002/alz.12745.
    PubMed     Abstract available

  75. LIU H, Xie Y, Wang X, Abboud MI, et al
    Exploring links between 2-oxoglutarate-dependent oxygenases and Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 19. doi: 10.1002/alz.12733.
    PubMed     Abstract available

  76. BATRA R, Arnold M, Worheide MA, Allen M, et al
    The landscape of metabolic brain alterations in Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 13. doi: 10.1002/alz.12714.
    PubMed     Abstract available

  77. WANG JT, Xu G, Ren RJ, Wang Y, et al
    The impacts of health insurance and resource on the burden of Alzheimer's disease and related dementias in the world population.
    Alzheimers Dement. 2022 Jul 12. doi: 10.1002/alz.12730.
    PubMed     Abstract available

  78. LIN Z, Lim C, Jiang D, Soldan A, et al
    Longitudinal changes in brain oxygen extraction fraction (OEF) in older adults: Relationship to markers of vascular and Alzheimer's pathology.
    Alzheimers Dement. 2022 Jul 6. doi: 10.1002/alz.12727.
    PubMed     Abstract available

  79. TIAN C, Stewart T, Hong Z, Guo Z, et al
    Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 2. doi: 10.1002/alz.12723.
    PubMed     Abstract available

  80. SALVADO G, Ferreira D, Operto G, Cumplido-Mayoral I, et al
    The protective gene dose effect of the APOE epsilon2 allele on gray matter volume in cognitively unimpaired individuals.
    Alzheimers Dement. 2022;18:1383-1395.
    PubMed     Abstract available

  81. KATSEL P, Fam P, Tan W, Khan S, et al
    Engagement of vascular early response genes typifies mild cognitive impairment.
    Alzheimers Dement. 2022;18:1357-1369.
    PubMed     Abstract available

    June 2022
  82. CHUNG J, Das A, Sun X, Sobreira DR, et al
    Genome-wide association and multi-omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women.
    Alzheimers Dement. 2022 Jun 30. doi: 10.1002/alz.12719.
    PubMed     Abstract available

  83. WEINER MW, Harvey D, Landau SM, Veitch DP, et al
    Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers.
    Alzheimers Dement. 2022 Jun 29. doi: 10.1002/alz.12712.
    PubMed     Abstract available

  84. ABDULRAHMAN H, van Dalen JW, den Brok M, Latimer CS, et al
    Hypertension and Alzheimer's disease pathology at autopsy: A systematic review.
    Alzheimers Dement. 2022 Jun 27. doi: 10.1002/alz.12707.
    PubMed     Abstract available

  85. WINGO TS, Gerasimov ES, Canon SM, Lah JJ, et al
    Alzheimer's disease genetic burden is associated with mid-life depression among persons with normal cognition.
    Alzheimers Dement. 2022 Jun 21. doi: 10.1002/alz.12716.
    PubMed     Abstract available

  86. CULLEN NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al
    Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models.
    Alzheimers Dement. 2022 Jun 14. doi: 10.1002/alz.12706.
    PubMed     Abstract available

  87. DELVENNE A, Gobom J, Tijms B, Bos I, et al
    Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology.
    Alzheimers Dement. 2022 Jun 14. doi: 10.1002/alz.12713.
    PubMed     Abstract available

  88. SINGH NA, Tosakulwong N, Graff-Radford J, Machulda MM, et al
    APOE epsilon4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease.
    Alzheimers Dement. 2022 Jun 12. doi: 10.1002/alz.12711.
    PubMed     Abstract available

  89. RISCHEL EB, Gejl M, Brock B, Rungby J, et al
    In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails.
    Alzheimers Dement. 2022 Jun 8. doi: 10.1002/alz.12701.
    PubMed     Abstract available

  90. GAO F, Lv X, Dai L, Wang Q, et al
    A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study.
    Alzheimers Dement. 2022 Jun 6. doi: 10.1002/alz.12700.
    PubMed     Abstract available

  91. GUSTAVSSON A, Norton N, Fast T, Frolich L, et al
    Global estimates on the number of persons across the Alzheimer's disease continuum.
    Alzheimers Dement. 2022 Jun 2. doi: 10.1002/alz.12694.
    PubMed     Abstract available

  92. SAWA M, Overk C, Becker A, Derse D, et al
    Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.
    Alzheimers Dement. 2022;18:1203-1234.
    PubMed     Abstract available

  93. SYRJANEN JA, Campbell MR, Algeciras-Schimnich A, Vemuri P, et al
    Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.
    Alzheimers Dement. 2022;18:1128-1140.
    PubMed     Abstract available

  94. LIU L, Kwak H, Lawton TL, Jin SX, et al
    An ultra-sensitive immunoassay detects and quantifies soluble Abeta oligomers in human plasma.
    Alzheimers Dement. 2022;18:1186-1202.
    PubMed     Abstract available

  95. SANZ-BLASCO R, Ruiz-Sanchez de Leon JM, Avila-Villanueva M, Valenti-Soler M, et al
    Transition from mild cognitive impairment to normal cognition: Determining the predictors of reversion with multi-state Markov models.
    Alzheimers Dement. 2022;18:1177-1185.
    PubMed     Abstract available

    May 2022
  96. VOGLEIN J, Franzmeier N, Morris JC, Dieterich M, et al
    Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease.
    Alzheimers Dement. 2022 May 24. doi: 10.1002/alz.12684.
    PubMed     Abstract available

  97. HU Y, Zhang Y, Zhang H, Gao S, et al
    Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk.
    Alzheimers Dement. 2022 May 22. doi: 10.1002/alz.12687.

  98. LUO J, Thomassen JQ, Hegazy SH, Rasmussen IJ, et al
    Reply to "Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk".
    Alzheimers Dement. 2022 May 22. doi: 10.1002/alz.12688.

  99. ASHLEIGH T, Swerdlow RH, Beal MF
    The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis.
    Alzheimers Dement. 2022 May 6. doi: 10.1002/alz.12683.
    PubMed     Abstract available

  100. SEXTON C, Snyder H, Beher D, Boxer AL, et al
    Current directions in tau research: Highlights from Tau 2020.
    Alzheimers Dement. 2022;18:988-1007.
    PubMed     Abstract available

  101. IMBIMBO BP, Ippati S, Watling M, Balducci C, et al
    A critical appraisal of tau-targeting therapies for primary and secondary tauopathies.
    Alzheimers Dement. 2022;18:1008-1037.
    PubMed     Abstract available

  102. PERRY BL, McConnell WR, Coleman ME, Roth AR, et al
    Why the cognitive "fountain of youth" may be upstream: Pathways to dementia risk and resilience through social connectedness.
    Alzheimers Dement. 2022;18:934-941.
    PubMed     Abstract available

    April 2022
  103. CHANG R, Trushina E, Zhu K, Zaidi SSA, et al
    Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 28. doi: 10.1002/alz.12675.
    PubMed     Abstract available

  104. PARK SY, Setiawan VW, White LR, Wu AH, et al
    Modifying effects of race and ethnicity and APOE on the association of physical activity with risk of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2022 Apr 27. doi: 10.1002/alz.12677.
    PubMed     Abstract available

  105. JESSEN F, Wolfsgruber S, Kleineindam L, Spottke A, et al
    Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.
    Alzheimers Dement. 2022 Apr 22. doi: 10.1002/alz.12674.
    PubMed     Abstract available

  106. QUAN L, Moreno-Gonzalez I, Xie Z, Gamez N, et al
    A near-infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 18. doi: 10.1002/alz.12673.
    PubMed     Abstract available

  107. TJANDRA D, Migrino RQ, Giordani B, Wiens J, et al
    Use of blood pressure measurements extracted from the electronic health record in predicting Alzheimer's disease: A retrospective cohort study at two medical centers.
    Alzheimers Dement. 2022 Apr 16. doi: 10.1002/alz.12676.
    PubMed     Abstract available

  108. TA PARK VM, Meyer OL, Tsoh JY, Kanaya AM, et al
    The Collaborative Approach for Asian Americans and Pacific Islanders Research and Education (CARE): A recruitment registry for Alzheimer's disease and related dementias, aging, and caregiver-related research.
    Alzheimers Dement. 2022 Apr 14. doi: 10.1002/alz.12667.
    PubMed     Abstract available

  109. MARTINEZ AE, Weissberger G, Kuklenyik Z, He X, et al
    The small HDL particle hypothesis of Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 13. doi: 10.1002/alz.12649.
    PubMed     Abstract available

  110. MIELKE MM, Aggarwal NT, Vila-Castelar C, Agarwal P, et al
    Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective.
    Alzheimers Dement. 2022 Apr 8. doi: 10.1002/alz.12662.
    PubMed     Abstract available

  111. WANG Y, Li M, Kazis LE, Xia W, et al
    Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.
    Alzheimers Dement. 2022 Apr 4. doi: 10.1002/alz.12665.
    PubMed     Abstract available

  112. LUCKETT PH, Chen C, Gordon BA, Wisch J, et al
    Biomarker clustering in autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 1. doi: 10.1002/alz.12661.
    PubMed     Abstract available

  113. NEUPANE A, Lenny B, Budde JP, Wang F, et al
    Replication study of AD-associated rare variants.
    Alzheimers Dement. 2022;18:858-862.

  114. AKINYEMI RO, Yaria J, Ojagbemi A, Guerchet M, et al
    Dementia in Africa: Current evidence, knowledge gaps, and future directions.
    Alzheimers Dement. 2022;18:790-809.
    PubMed     Abstract available

  115. MURA T, Coley N, Amieva H, Berr C, et al
    Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials.
    Alzheimers Dement. 2022;18:676-687.
    PubMed     Abstract available

  116. LINDBOHM JV, Mars N, Walker KA, Singh-Manoux A, et al
    Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies.
    Alzheimers Dement. 2022;18:612-624.
    PubMed     Abstract available

  117. POURHADI N, Morch LS, Holm EA, Torp-Pedersen CT, et al
    Vaginal estrogen and association with dementia: A nationwide population-based study.
    Alzheimers Dement. 2022;18:625-634.
    PubMed     Abstract available

  118. MIELKE MM, Aakre JA, Algeciras-Schimnich A, Proctor NK, et al
    Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.
    Alzheimers Dement. 2022;18:602-611.
    PubMed     Abstract available

  119. CASANOVA R, Hsu FC, Barnard RT, Anderson AM, et al
    Comparing data-driven and hypothesis-driven MRI-based predictors of cognitive impairment in individuals from the Atherosclerosis Risk in Communities (ARIC) study.
    Alzheimers Dement. 2022;18:561-571.
    PubMed     Abstract available

  120. YANG HS, Zhang C, Carlyle BC, Zhen SY, et al
    Plasma IL-12/IFN-gamma axis predicts cognitive trajectories in cognitively unimpaired older adults.
    Alzheimers Dement. 2022;18:645-653.
    PubMed     Abstract available

    March 2022
  121. BRODY M, Agronin M, Herskowitz BJ, Bookheimer SY, et al
    Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 31. doi: 10.1002/alz.12651.
    PubMed     Abstract available

  122. ZHANG X, Tong T, Chang A, Ang TFA, et al
    Midlife lipid and glucose levels are associated with Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 23. doi: 10.1002/alz.12641.
    PubMed     Abstract available

  123. JACOBS HIL, Becker JA, Kwong K, Munera D, et al
    Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 17. doi: 10.1002/alz.12656.
    PubMed     Abstract available

  124. LI P, Gao L, Yu L, Zheng X, et al
    Daytime napping and Alzheimer's dementia: A potential bidirectional relationship.
    Alzheimers Dement. 2022 Mar 17. doi: 10.1002/alz.12636.
    PubMed     Abstract available

  125. COE NB, White L, Oney M, Basu A, et al
    Public spending on acute and long-term care for Alzheimer's disease and related dementias.
    Alzheimers Dement. 2022 Mar 16. doi: 10.1002/alz.12657.
    PubMed     Abstract available

  126. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2022 Mar 14. doi: 10.1002/alz.12638.
    PubMed     Abstract available

  127. LIU L, Lauro BM, He A, Lee H, et al
    Identification of the Abeta37/42 peptide ratio in CSF as an improved Abeta biomarker for Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 12. doi: 10.1002/alz.12646.
    PubMed     Abstract available

  128. WINDER Z, Sudduth TL, Anderson S, Patel E, et al
    Examining the association between blood-based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort.
    Alzheimers Dement. 2022 Mar 10. doi: 10.1002/alz.12639.
    PubMed     Abstract available

  129. BREITNER JCS, Dodge HH, Khachaturian ZS, Khachaturian AS, et al
    "Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?
    Alzheimers Dement. 2022 Mar 4. doi: 10.1002/alz.12633.

  130. Alzheimer's Association welcomes new Medical and Scientific Advisory Group members.
    Alzheimers Dement. 2022 Mar 4. doi: 10.1002/alz.12621.

  131. O'BRYANT SE, Petersen M, Hall J, Johnson LA, et al
    Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12647.
    PubMed     Abstract available

  132. CONNOLLY K, Lehoux M, O'Rourke R, Assetta B, et al
    Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12612.
    PubMed     Abstract available

  133. STOCKER H, Beyer L, Perna L, Rujescu D, et al
    Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12614.
    PubMed     Abstract available

  134. CUMMINGS J, Salloway S
    Aducanumab: Appropriate use recommendations.
    Alzheimers Dement. 2022;18:531-533.

  135. PETERSON A, Clapp J, Largent EA, Harkins K, et al
    What is paradoxical lucidity? The answer begins with its definition.
    Alzheimers Dement. 2022;18:513-521.
    PubMed     Abstract available

  136. BARIL AA, Beiser AS, Sanchez E, Mysliwiec V, et al
    Insomnia symptom severity and cognitive performance: Moderating role of APOE genotype.
    Alzheimers Dement. 2022;18:408-421.
    PubMed     Abstract available

    February 2022
  137. GIETL AF, Frisoni GB
    Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.
    Alzheimers Dement. 2022 Feb 27. doi: 10.1002/alz.12605.
    PubMed     Abstract available

  138. KETCHUM FB, Chin NA, Grill J, Gleason CE, et al
    Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12620.
    PubMed     Abstract available

  139. ASHFORD MT, Raman R, Miller G, Donohue MC, et al
    Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12640.
    PubMed     Abstract available

    Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12618.
    PubMed     Abstract available

  141. XIONG C, Luo J, Schindler SE, Fagan AM, et al
    Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12608.
    PubMed     Abstract available

  142. MONI F, Petersen ME, Zhang F, Lao PJ, et al
    Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12627.
    PubMed     Abstract available

  143. LEVIN J, Voglein J, Quiroz YT, Bateman RJ, et al
    Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12624.
    PubMed     Abstract available

  144. QUIROZ YT, Solis M, Aranda MP, Arbaje AI, et al
    Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12589.
    PubMed     Abstract available

  145. SEXTON C, Solis M, Aharon-Peretz J, Alexopoulos P, et al
    Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium.
    Alzheimers Dement. 2022 Feb 20. doi: 10.1002/alz.12588.
    PubMed     Abstract available

  146. MECCA AP, O'Dell RS, Sharp ES, Banks ER, et al
    Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [(11) C]UCB-J.
    Alzheimers Dement. 2022 Feb 17. doi: 10.1002/alz.12582.
    PubMed     Abstract available

  147. SUCHY-DICEY A, Howard B, Longstreth WT Jr, Reiman EM, et al
    APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study.
    Alzheimers Dement. 2022 Feb 10. doi: 10.1002/alz.12573.
    PubMed     Abstract available

  148. KRELL-ROESCH J, Rakusa M, Syrjanen JA, van Harten AC, et al
    Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12557.
    PubMed     Abstract available

  149. CLAES C, England WE, Danhash EP, Kiani Shabestari S, et al
    The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12577.
    PubMed     Abstract available

  150. HU WT
    Reporting and social construction of race in Alzheimer's disease clinical trials.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12609.

  151. ASTILLERO-LOPEZ V, Gonzalez-Rodriguez M, Villar-Conde S, Flores-Cuadrado A, et al
    Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease: Stereological layer-specific assessment and proteomic analysis.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12580.
    PubMed     Abstract available

  152. FLACH M, Leu C, Martinisi A, Skachokova Z, et al
    Trans-seeding of Alzheimer-related tau protein by a yeast prion.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12581.
    PubMed     Abstract available

  153. PRADOS MJ, Liu Y, Jun H, Lam J, et al
    Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12578.
    PubMed     Abstract available

  154. BABULAL GM, Franzen S, Abner EL, Smith JE, et al
    Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12611.

  155. JUN GR, You Y, Zhu C, Meng G, et al
    Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE varepsilon2 for Alzheimer's disease.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12607.
    PubMed     Abstract available

  156. VARDARAJAN BN, Reyes-Dumeyer D, Piriz AL, Lantigua RA, et al
    Progranulin mutations in clinical and neuropathological Alzheimer's disease.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12567.
    PubMed     Abstract available

  157. REIKEN S, Sittenfeld L, Dridi H, Liu Y, et al
    Alzheimer's-like signaling in brains of COVID-19 patients.
    Alzheimers Dement. 2022 Feb 3. doi: 10.1002/alz.12558.
    PubMed     Abstract available

  158. RUTHIRAKUHAN M, Ismail Z, Herrmann N, Gallagher D, et al
    Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12519.
    PubMed     Abstract available

  159. REIMAN EM, Mattke S, Kordower JH, Khachaturian ZS, et al
    Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12533.

  160. Applications being accepted for the Alzheimer's Association Interdisciplinary Summer Research Institute.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12585.

  161. VILA-CASTELAR C, Tariot PN, Sink KM, Clayton D, et al
    Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12552.
    PubMed     Abstract available

  162. WAGNER M, Wilson RS, Leurgans SE, Boyle PA, et al
    Quantifying longitudinal cognitive resilience to Alzheimer's disease and other neuropathologies.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12576.
    PubMed     Abstract available

  163. ERATNE D, Loi SM, Li QX, Stehmann C, et al
    Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12549.
    PubMed     Abstract available

  164. O'BRYANT S, Petersen M, Hall J, Johnson L, et al
    Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study.
    Alzheimers Dement. 2022;18:240-250.
    PubMed     Abstract available

  165. NAUEN DW, Troncoso JC
    Amyloid-beta is present in human lymph nodes and greatly enriched in those of the cervical region.
    Alzheimers Dement. 2022;18:205-210.
    PubMed     Abstract available

  166. KREISL WC, Lao PJ, Johnson A, Tomljanovic Z, et al
    Patterns of tau pathology identified with (18) F-MK-6240 PET imaging.
    Alzheimers Dement. 2022;18:272-282.
    PubMed     Abstract available

  167. SCHMUTTE T, Olfson M, Maust DT, Xie M, et al
    Suicide risk in first year after dementia diagnosis in older adults.
    Alzheimers Dement. 2022;18:262-271.
    PubMed     Abstract available

    January 2022
  168. CALDWELL AB, Liu Q, Zhang C, Schroth GP, et al
    Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease.
    Alzheimers Dement. 2022 Jan 27. doi: 10.1002/alz.12553.
    PubMed     Abstract available

  169. WANG T, Huynh K, Giles C, Mellett NA, et al
    APOE epsilon2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.
    Alzheimers Dement. 2022 Jan 25. doi: 10.1002/alz.12538.
    PubMed     Abstract available

  170. JORDA-SIQUIER T, Petrel M, Kouskoff V, Smailovic U, et al
    APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?
    Alzheimers Dement. 2022 Jan 25. doi: 10.1002/alz.12546.
    PubMed     Abstract available

  171. FRONTERA JA, Boutajangout A, Masurkar AV, Betensky RA, et al
    Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
    Alzheimers Dement. 2022 Jan 13. doi: 10.1002/alz.12556.
    PubMed     Abstract available

  172. YAO J, Liu Y, Sun B, Zhan X, et al
    Increased RyR2 open probability induces neuronal hyperactivity and memory loss with or without Alzheimer's disease-causing gene mutations.
    Alzheimers Dement. 2022 Jan 5. doi: 10.1002/alz.12543.
    PubMed     Abstract available

  173. NAZARIAN A, Loika Y, He L, Culminskaya I, et al
    Genome-wide analysis identified abundant genetic modulators of contributions of the apolipoprotein E alleles to Alzheimer's disease risk.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12540.
    PubMed     Abstract available

  174. REYES-DUMEYER D, Faber K, Vardarajan B, Goate A, et al
    The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12514.
    PubMed     Abstract available

  175. QIU S, Hu Y, Cheng L
    BIN1 rs744373 located in enhancers of brain tissues upregulates BIN1 mRNA expression, thereby leading to Alzheimer's disease.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12548.

  176. ZAMOLODCHIKOV D, Duffield M, Macdonald LE, Alessandri-Haber N, et al
    Accumulation of high molecular weight kininogen in the brains of Alzheimer's disease patients may affect microglial function by altering phagocytosis and lysosomal cathepsin activity.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12531.
    PubMed     Abstract available

  177. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring announces new editor-in-chief for open access, peer reviewed journal.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12517.

    Solomon Carter Fuller: Alzheimer's contemporary and American pioneer.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12551.

  179. JAKEL L, De Kort AM, Klijn CJM, Schreuder FHBM, et al
    Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis.
    Alzheimers Dement. 2022;18:10-28.
    PubMed     Abstract available

  180. ZHAO Y, Kuca K, Wu W, Wang X, et al
    Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases.
    Alzheimers Dement. 2022;18:152-158.
    PubMed     Abstract available

  181. BUTT OH, Meeker KL, Wisch JK, Schindler SE, et al
    Network dysfunction in cognitively normal APOE epsilon4 carriers is related to subclinical tau.
    Alzheimers Dement. 2022;18:116-126.
    PubMed     Abstract available

  182. VOGT NM, Hunt JFV, Adluru N, Ma Y, et al
    Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.
    Alzheimers Dement. 2022;18:65-76.
    PubMed     Abstract available

    December 2021
  183. DELABY C, Teunissen CE, Blennow K, Alcolea D, et al
    Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.
    Alzheimers Dement. 2021 Dec 22. doi: 10.1002/alz.12545.
    PubMed     Abstract available

  184. MING C, Wang M, Wang Q, Neff R, et al
    Whole genome sequencing-based copy number variations reveal novel pathways and targets in Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 17. doi: 10.1002/alz.12507.
    PubMed     Abstract available

  185. HAWKINSON TR, Clarke HA, Young LEA, Conroy LR, et al
    In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains.
    Alzheimers Dement. 2021 Dec 15. doi: 10.1002/alz.12523.
    PubMed     Abstract available

  186. LIM U, Wang S, Park SY, Bogumil D, et al
    Risk of Alzheimer's disease and related dementia by sex and race/ethnicity: The Multiethnic Cohort Study.
    Alzheimers Dement. 2021 Dec 9. doi: 10.1002/alz.12528.
    PubMed     Abstract available

  187. GORDON MN, Heneka MT, Le Page LM, Limberger C, et al
    Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12488.
    PubMed     Abstract available

  188. DE KORT AM, Kuiperij HB, Kersten I, Versleijen AAM, et al
    Normal cerebrospinal fluid concentrations of PDGFRbeta in patients with cerebral amyloid angiopathy and Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12506.
    PubMed     Abstract available

  189. SILVERMAN W, Krinsky-McHale SJ, Zigman WB, Schupf N, et al
    Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12520.
    PubMed     Abstract available

  190. SAROJA SR, Sharma A, Hof PR, Pereira AC, et al
    Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12518.
    PubMed     Abstract available

  191. GLEASON CE, Zuelsdorff M, Gooding DC, Kind AJH, et al
    Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.
    Alzheimers Dement. 2021 Dec 6. doi: 10.1002/alz.12511.
    PubMed     Abstract available

  192. HAEGER A, Bottlaender M, Lagarde J, Porciuncula Baptista R, et al
    What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12501.
    PubMed     Abstract available

  193. AAIC 2021: The promise of Alzheimer's research.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12500.

  194. FRANK B, Ally M, Brekke B, Zetterberg H, et al
    Plasma p-tau181 shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12508.
    PubMed     Abstract available

  195. STATHAS S, Alvarez VE, Xia W, Nicks R, et al
    Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12502.
    PubMed     Abstract available

  196. BUCKLES VD, Xiong C, Bateman RJ, Hassenstab J, et al
    Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12505.
    PubMed     Abstract available

  197. STRINGER C, Smithroat N, Samus QM, Johnston D, et al
    From research to realization: How a Texas health plan implemented an academic model of care for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 8:e054058.
    PubMed     Abstract available

  198. MENENGIC KN, Yeldan I, Cinar N, Sahiner TA, et al
    Effectiveness of home-based telerehabilitation in mild to moderate Alzheimer's disease: A randomised controlled study.
    Alzheimers Dement. 2021;17 Suppl 8:e053406.
    PubMed     Abstract available

  199. ASCHETTINO LA, Labyak CA, Sealey-Potts C
    Nutritional treatments for Alzheimer's disease: A narrative review.
    Alzheimers Dement. 2021;17 Suppl 8:e053172.
    PubMed     Abstract available

  200. LEE JH, Kim DY, Kim MG, Kang H, et al
    Preventing cognitive decline in older adults with mild cognitive impairment using integrated Korean and Western treatments: Initial results.
    Alzheimers Dement. 2021;17 Suppl 8:e052545.
    PubMed     Abstract available

  201. GELDMACHER DS, Christopher R, Anderson M, Bero AW, et al
    Development of a site readiness framework to improve health system preparedness for potential new Alzheimer's disease therapies.
    Alzheimers Dement. 2021;17 Suppl 8:e057672.
    PubMed     Abstract available

  202. KEELY AJ
    The first female engineer at General Motor's descent into Alzheimer's with sundowners: A daughter's scholarly research and case study as caregiver.
    Alzheimers Dement. 2021;17 Suppl 8:e050143.
    PubMed     Abstract available

  203. FLATT JD, Pollock K, Lee R, Song Y, et al
    Feasibility of the Savvy Caregiver program for care providers of LGBTQ adults living with Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021;17 Suppl 8:e055633.
    PubMed     Abstract available

  204. MILLER DR, Jasuja G, Davila HW, Palnati M, et al
    Care processes related to clinical detection of Alzheimer's disease in the U.S. Veterans Affairs Health Care System.
    Alzheimers Dement. 2021;17 Suppl 8:e054149.
    PubMed     Abstract available

    Stimulation of cerebral angiogenesis and neurogenesis with transcatheter intracerebral laser photobiomodulation therapy during dementia in patients with Alzheimer's and Binswanger's disease.
    Alzheimers Dement. 2021;17 Suppl 8:e054945.
    PubMed     Abstract available

  206. GONZALEZ A, Camila C, Maccioni RB
    Alzheimer's disease: A potential diabetes type 3.
    Alzheimers Dement. 2021;17 Suppl 2:e058533.
    PubMed     Abstract available

  207. MOYLAN C, Cao TV, Huynh QS, Pratap A, et al
    Exercise-Induced Alterations in TrkB expression in the 5XFAD Mouse Model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058733.
    PubMed     Abstract available

  208. GAITAN JM, Dubal DB, Okonkwo OC
    Circulating klotho is elevated in cerebrospinal fluid, but not serum, among KLOTHO KL-VS allele carriers at risk for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058612.
    PubMed     Abstract available

  209. COULON A, Mendes T, Kilinc D, Dumont J, et al
    High-content screening of Alzheimer's disease genetic risk factors based on synaptic density analysis.
    Alzheimers Dement. 2021;17 Suppl 2:e058660.
    PubMed     Abstract available

  210. TSAI AP, Lin PB, Dong C, Moutinho M, et al
    Impact of PLCG2 expression on Microglial Biology and Disease Pathogenesis in Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058740.
    PubMed     Abstract available

  211. HUANG CW, Hart GW
    Decreased O-GlcNAcylation and mitochondrial dysfunction are involving in low glucose induced Alzheimer's disease-like phenotype in induced pluripotent stem cell-derived neurons.
    Alzheimers Dement. 2021;17 Suppl 2:e058620.
    PubMed     Abstract available

  212. BRACH TL, Gaitan JM, Okonkwo OC
    Effect of Aerobic Exercise Training on Mood and Cognition in Adults at Risk for Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058523.
    PubMed     Abstract available

  213. LIN PB, Tsai AP, Nho K, Lamb BT, et al
    INPP5D regulates the amyloid pathology in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058724.
    PubMed     Abstract available

  214. KUMAR A, Doran E, Martini AC, Head E, et al
    CAA and related co-morbidities in Down syndrome and Alzheimer disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058726.
    PubMed     Abstract available

    The role of lycopene on the hippocampus of rat model of lipopolysaccharide-induced Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058528.
    PubMed     Abstract available

  216. YEATES C, Sarkar A, Deshpande P, Kango-Singh M, et al
    A Two-Clone approach to study signaling interactions among neuronal cells in a pre-clinical Alzheimer's Disease model.
    Alzheimers Dement. 2021;17 Suppl 2:e058690.
    PubMed     Abstract available

  217. GOMEZ J JR, Villegas-Lanau CA, Mesa A Sr
    Colocalization of the beta amyloid peptide with bacteria in postmortem brain tissue of patients with familial Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058692.
    PubMed     Abstract available

  218. SUNG K, Yang F, Noble W, Jimenez-Sanchez M, et al
    Investigating the non-cell autonomous role of glial chaperones in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058572.
    PubMed     Abstract available

  219. GOMEZ J JR, Villegas-Lanau CA, Mesa A Sr
    Human Herpesvirus detection and identification in postmortem brain tissue of patients with Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058693.
    PubMed     Abstract available

  220. SCHRAUBEN M, Smith AR, Washer S, Dempster E, et al
    Investigating epigenetic loci implicated in Alzheimer's disease via the CRISPR-Cas9 system.
    Alzheimers Dement. 2021;17 Suppl 2:e058573.
    PubMed     Abstract available

  221. TALIYAN R, Kakoty V, Kc S, Kumari S, et al
    Fibroblast Growth Factor 21 and Autophagy Modulation Ameliorates Amyloid beta-Induced Alzheimer Disease Pathology in Rats.
    Alzheimers Dement. 2021;17 Suppl 2:e058695.
    PubMed     Abstract available

  222. YANG F, Sung K, Sanchez MJ
    Investigating the secretion of small heat shock proteins in reactive astrocytes in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058498.
    PubMed     Abstract available

  223. ROSENE MJ, Hsu S, Martinez R, Norton J, et al
    Defining the role of PLD3 in Alzheimer's disease pathology.
    Alzheimers Dement. 2021;17 Suppl 2:e058730.
    PubMed     Abstract available

  224. TREMBLAY JP, Tremblay G, Guyon A, Joel R, et al
    Insertion of the Icelandic mutation (A673T) in the APP gene using the CRISPR/Cas9 base editing and Prime editing technologies, a preventive treatment for Alzheimer?
    Alzheimers Dement. 2021;17 Suppl 2:e058710.
    PubMed     Abstract available

  225. CHEN J, Samoylova NG, Cummings MG
    TOMM40, a risk gene for Alzheimer's disease, is upregulated during proinflammatory response.
    Alzheimers Dement. 2021;17 Suppl 2:e058711.
    PubMed     Abstract available

  226. MCARDLE CJ, Niere F, Uneri A, Raab-Graham KF, et al
    Alterations in dendritic GABAB receptor expression in an Alzheimer's disease mouse model.
    Alzheimers Dement. 2021;17 Suppl 2:e058557.
    PubMed     Abstract available

  227. DESHPANDE P, Chen CY, Yeates C, Chen CH, et al
    miR-277 targets hid to ameliorate Abeta42-mediated neurodegeneration in Drosophila eye model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058678.
    PubMed     Abstract available

  228. ZHAO P, Mangleburg CG, Al-Ramahi I, Botas J, et al
    Systems genetic dissection of Alzheimer's disease brain gene expression networks.
    Alzheimers Dement. 2021;17 Suppl 2:e058716.
    PubMed     Abstract available

  229. MUMFORD P, Noy S, Tybulewicz VL, Fisher E, et al
    Preclinical modelling in the mouse of altered neuroinflammation in Alzheimer's disease - Down syndrome.
    Alzheimers Dement. 2021;17 Suppl 2:e058441.
    PubMed     Abstract available

  230. TIPTON AE, George J, Ratner M, Farb D, et al
    Data from single nuclei RNA-sequencing reveals a prodromal gene network response in excitatory neurons of a humanized rat Alzheimer's disease model.
    Alzheimers Dement. 2021;17 Suppl 2:e058589.
    PubMed     Abstract available

  231. TAYLOR AL, Davis DE Jr, Codreanu SG, Harrison FE, et al
    Targeted and untargeted mass spectrometry reveals impact of high fat diet on peripheral amino acid regulation in a mouse model of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058428.
    PubMed     Abstract available

    Exercise-induced metabolic changes in astrocytes in the 5xFAD mouse model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058627.
    PubMed     Abstract available

  233. SRIVASTAV A, Mohideen SS
    Intestinal microbial dysbiosis induced tau accumulation establishes a gut-brain correlation for pathology Alzheimer's disease in Drosophila melanogaster.
    Alzheimers Dement. 2021;17 Suppl 2:e058708.
    PubMed     Abstract available

  234. HERSH SW, You Y, Aslebagh R, Shaffer SA, et al
    Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells.
    Alzheimers Dement. 2021;17 Suppl 2:e058592.
    PubMed     Abstract available

  235. PRATER KE, Green KJ, Chiou KL, Smith CL, et al
    Microglia subtype transcriptomes differ between Alzheimer Disease and control human postmortem brain samples.
    Alzheimers Dement. 2021;17 Suppl 2:e058474.
    PubMed     Abstract available

  236. CZAPLICKI AM, Gaitan JM, Bendlin BB, Johnson SC, et al
    The Interaction between Ventricle to Brain Ratio and Serum Klotho on Cognition in Older Adults at Risk for Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058632.
    PubMed     Abstract available

  237. BABATOPE EY, Acosta-Franco JA, Garcia-Vazquez MS, Ramirez-Acosta AA, et al
    Applying a deep learning approach focusing on spatiotemporal features in early diagnosis of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058635.
    PubMed     Abstract available

  238. MCINTYRE CC, Okonkwo OC, Gaitan JM, Bendlin BB, et al
    Effect of insulin resistance on the association between cardiorespiratory fitness and cognition in adults at risk for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058683.
    PubMed     Abstract available

  239. WANG RP, Leung WK, Goto T, Ho JY, et al
    IL-1 beta and TNF-alpha play an essential role in modulating the risk of both periodontitis and Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058464.
    PubMed     Abstract available

  240. MEMUDU AE, Waziri RJ
    An investigative study to demonstrate the link between combined intake of marijuana and codeine in Alzheimer's disease pathology.
    Alzheimers Dement. 2021;17 Suppl 12:e058465.
    PubMed     Abstract available

  241. RISHITHA N, Muthuraman A
    Therapeutic investigation of alpha napthoflavone in the intracerebroventricular injection of L-cysteine induced vascular dementia in rats.
    Alzheimers Dement. 2021;17 Suppl 12:e058344.
    PubMed     Abstract available

  242. ABDULKADIR TS, Isa AS, Dawud FA, Ayo JO, et al
    Effect of taurine and camel milk on amyloid beta peptide concentration and oxidative stress changes in aluminium chloride-induced Alzheimer's disease rats.
    Alzheimers Dement. 2021;17 Suppl 12:e058642.
    PubMed     Abstract available

  243. OKHUEVBIE DO, Awolaja S, Balogun Z
    Evaluation of the effect of Donepezil hydrochloride on Ethanol-induced hippocampal damage.
    Alzheimers Dement. 2021;17 Suppl 12:e058353.
    PubMed     Abstract available

  244. K C S, Kakoty VK, Taliyan R
    Development and Validation of PEG-PCL Based Nanoformulation of Rosiglitazone and Evaluation of its Brain Selectivity in Mice Model of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058674.
    PubMed     Abstract available

  245. TORT-MERINO A, Tarnanas I, Bugler M, Harms R, et al
    ALTOIDA-iADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e057982.
    PubMed     Abstract available

  246. ROWE EM, Louadi S, Koch E, Kuhlmann N, et al
    A Month in Neurodegenerative Disease Research (AMiNDR): The evolution of an open-access podcast series for Alzheimer's researchers.
    Alzheimers Dement. 2021;17 Suppl 11:e053287.
    PubMed     Abstract available

  247. YUAN F, Lopez RP, Crane M, Montgomery A, et al
    Feasibility and acceptance of robotic care of Alzheimer's disease and related dementia.
    Alzheimers Dement. 2021;17 Suppl 11:e052585.
    PubMed     Abstract available

  248. KUHNEL L, Bouteloup V, Lespinasse J, Chene G, et al
    Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study.
    Alzheimers Dement. 2021;17:1938-1949.
    PubMed     Abstract available

  249. GOLD BT, Shao X, Sudduth TL, Jicha GA, et al
    Water exchange rate across the blood-brain barrier is associated with CSF amyloid-beta 42 in healthy older adults.
    Alzheimers Dement. 2021;17:2020-2029.
    PubMed     Abstract available

  250. XU Y, Chen Z, Wey HY, Liang Y, et al
    Molecular imaging of NAD(+) -dependent deacetylase SIRT1 in the brain.
    Alzheimers Dement. 2021;17:1988-1997.
    PubMed     Abstract available

    November 2021
  251. VERBERK IMW, Misdorp EO, Koelewijn J, Ball AJ, et al
    Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.
    Alzheimers Dement. 2021 Nov 29. doi: 10.1002/alz.12510.
    PubMed     Abstract available

    Hypothesis: Modulation of microglial phenotype in Alzheimer's disease drives neurodegeneration.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12503.
    PubMed     Abstract available

  253. JIA L, Yang J, Zhu M, Pang Y, et al
    A metabolite panel that differentiates Alzheimer's disease from other dementia types.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12484.
    PubMed     Abstract available

  254. WEINTRAUB S, Karpouzian-Rogers T, Peipert JD, Nowinski C, et al
    ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12497.
    PubMed     Abstract available

  255. JUTKOWITZ E, Halladay C, Tsai J, Hooshyar D, et al
    Prevalence of Alzheimer's disease and related dementias among veterans experiencing housing insecurity.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12476.
    PubMed     Abstract available

  256. HORGUSLUOGLU E, Neff R, Song WM, Wang M, et al
    Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12468.
    PubMed     Abstract available

  257. BOADA M, Lopez OL, Olazaran J, Nunez L, et al
    Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
    Alzheimers Dement. 2021 Nov 2. doi: 10.1002/alz.12477.
    PubMed     Abstract available

  258. EZZATI A, Abdulkadir A, Jack CR Jr, Thompson PM, et al
    Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia.
    Alzheimers Dement. 2021;17:1855-1867.
    PubMed     Abstract available

  259. TAHIRA AC, Verjovski-Almeida S, Ferreira ST
    Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients.
    Alzheimers Dement. 2021;17:1818-1831.
    PubMed     Abstract available

    October 2021
  260. TOSUN D, Demir Z, Veitch DP, Weintraub D, et al
    Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.
    Alzheimers Dement. 2021 Oct 14. doi: 10.1002/alz.12480.
    PubMed     Abstract available

  261. MEYERS EA, Amouyel P, Bovenkamp DE, Carrillo MC, et al
    Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic.
    Alzheimers Dement. 2021 Oct 1. doi: 10.1002/alz.12472.
    PubMed     Abstract available

  262. Alzheimer's Disease Interventions: Implications of therapeutic promises amidst questions and doubts about clinically meaningful outcomes.
    Alzheimers Dement. 2021;17:1591-1594.

  263. DE MAULEON A, Ismail Z, Rosenberg P, Miller D, et al
    Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
    Alzheimers Dement. 2021;17:1687-1697.
    PubMed     Abstract available

  264. DAMOTTE V, van der Lee SJ, Chouraki V, Grenier-Boley B, et al
    Plasma amyloid beta levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.
    Alzheimers Dement. 2021;17:1663-1674.
    PubMed     Abstract available

  265. BANGEN KJ, Thomas KR, Weigand AJ, Edmonds EC, et al
    Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI.
    Alzheimers Dement. 2021;17:1756-1762.
    PubMed     Abstract available

  266. MEZ J, Alosco ML, Daneshvar DH, Saltiel N, et al
    Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology.
    Alzheimers Dement. 2021;17:1709-1724.
    PubMed     Abstract available

  267. GALVIN JE, Chrisphonte S, Cohen I, Greenfield KK, et al
    Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD-MOD).
    Alzheimers Dement. 2021;17:1675-1686.
    PubMed     Abstract available

  268. YANG C, Li X, Zhang J, Chen Y, et al
    Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative.
    Alzheimers Dement. 2021;17:1610-1618.
    PubMed     Abstract available

    September 2021
  269. FRANZEN S, Smith JE, van den Berg E, Rivera Mindt M, et al
    Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.
    Alzheimers Dement. 2021 Sep 30. doi: 10.1002/alz.12433.
    PubMed     Abstract available

  270. PICARD C, Nilsson N, Labonte A, Auld D, et al
    Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12442.
    PubMed     Abstract available

  271. JICHA GA, Abner EL, Arnold SE, Carrillo MC, et al
    Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12461.
    PubMed     Abstract available

  272. CUMMINGS JL, Goldman DP, Simmons-Stern NR, Ponton E, et al
    The costs of developing treatments for Alzheimer's disease: A retrospective exploration.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12450.
    PubMed     Abstract available

  273. VEITCH DP, Weiner MW, Aisen PS, Beckett LA, et al
    Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12422.
    PubMed     Abstract available

  274. WANG C, Wang Z, Xie B, Shi X, et al
    Binaural processing deficit and cognitive impairment in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12464.
    PubMed     Abstract available

  275. MATTKE S, Hanson M
    Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12470.
    PubMed     Abstract available

  276. PHILLIPS JS, Nitchie FJ 4th, Da Re F, Olm CA, et al
    Rates of longitudinal change in (18) F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 13. doi: 10.1002/alz.12456.
    PubMed     Abstract available

  277. ZHANG L, Du Rietz E, Kuja-Halkola R, Dobrosavljevic M, et al
    Attention-deficit/hyperactivity disorder and Alzheimer's disease and any dementia: A multi-generation cohort study in Sweden.
    Alzheimers Dement. 2021 Sep 9. doi: 10.1002/alz.12462.
    PubMed     Abstract available

  278. CHATTERJEE P, Pedrini S, Ashton NJ, Tegg M, et al
    Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12447.
    PubMed     Abstract available

  279. MARTERSTECK A, Sridhar J, Coventry C, Weintraub S, et al
    Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12445.
    PubMed     Abstract available

  280. LOGSDON AF, Francis KL, Richardson NE, Hu SJ, et al
    Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12451.
    PubMed     Abstract available

  281. MA Y, Yu L, Olah M, Smith R, et al
    Epigenomic features related to microglia are associated with attenuated effect of APOE epsilon4 on Alzheimer's disease risk in humans.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12425.
    PubMed     Abstract available

  282. REN RJ, Huang Q, Xu G, Gu K, et al
    Association between Alzheimer's disease and risk of cancer: A retrospective cohort study in Shanghai, China.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12436.
    PubMed     Abstract available

  283. PEGUEROLES J, Montal V, Bejanin A, Vilaplana E, et al
    AMYQ: An index to standardize quantitative amyloid load across PET tracers.
    Alzheimers Dement. 2021;17:1499-1508.
    PubMed     Abstract available

    August 2021
  284. GHAZARIAN AL, Haim T, Sauma S, Katiyar P, et al
    National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.
    Alzheimers Dement. 2021 Aug 10. doi: 10.1002/alz.12392.
    PubMed     Abstract available

  285. WANG Q, Davis PB, Gurney ME, Xu R, et al
    COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US.
    Alzheimers Dement. 2021;17:1297-1306.
    PubMed     Abstract available

  286. PIERUCCINI-FARIA F, Black SE, Masellis M, Smith EE, et al
    Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.
    Alzheimers Dement. 2021;17:1317-1328.
    PubMed     Abstract available

  287. BAUCKNEHT M, Chincarini A, Brendel M, Rominger A, et al
    Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium project.
    Alzheimers Dement. 2021;17:1277-1286.
    PubMed     Abstract available

  288. GIANATTASIO KZ, Bennett EE, Wei J, Mehrotra ML, et al
    Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC.
    Alzheimers Dement. 2021;17:1265-1276.
    PubMed     Abstract available

    July 2021
  289. GARNIER-CRUSSARD A, Bougacha S, Wirth M, Dautricourt S, et al
    White matter hyperintensity topography in Alzheimer's disease and links to cognition.
    Alzheimers Dement. 2021 Jul 28. doi: 10.1002/alz.12410.
    PubMed     Abstract available

  290. BOADA M, Rodrigo A, Jessen F, Wimblad B, et al
    Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12441.
    PubMed     Abstract available

  291. HOSCHEIDT S, Sanderlin AH, Baker LD, Jung Y, et al
    Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12421.
    PubMed     Abstract available

  292. VAN HARTEN AC, Wiste HJ, Weigand SD, Mielke MM, et al
    Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12406.
    PubMed     Abstract available

  293. KULMINSKI AM, Philipp I, Loika Y, He L, et al
    Protective association of the epsilon2/epsilon3 heterozygote with Alzheimer's disease is strengthened by TOMM40-APOE variants in men.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12413.
    PubMed     Abstract available

  294. BOCHE D, Gordon MN
    Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease.
    Alzheimers Dement. 2021 Jul 5. doi: 10.1002/alz.12389.
    PubMed     Abstract available

  295. BAO H, Liu Y, Zhang M, Chen Z, et al
    Increased beta-site APP cleaving enzyme 1-mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment.
    Alzheimers Dement. 2021;17:1097-1108.
    PubMed     Abstract available

    June 2021
  296. ZHANG X, Farrell JJ, Tong T, Hu J, et al
    Association of mitochondrial variants and haplogroups identified by whole exome sequencing with Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12396.
    PubMed     Abstract available

  297. TEERLINK CC, Miller JB, Vance EL, Staley LA, et al
    Analysis of high-risk pedigrees identifies 12 candidate variants for Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12397.
    PubMed     Abstract available

  298. ZHONG W, Wu A, Berglund K, Gu X, et al
    Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12398.
    PubMed     Abstract available

  299. JANELIDZE S, Palmqvist S, Leuzy A, Stomrud E, et al
    Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42/Abeta40 and p-tau.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12395.
    PubMed     Abstract available

  300. BIRKENBIHL C, Salimi Y, Frohlich H
    Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling.
    Alzheimers Dement. 2021 Jun 9. doi: 10.1002/alz.12387.
    PubMed     Abstract available

  301. LOPEZ-RODRIGUEZ AB, Hennessy E, Murray CL, Nazmi A, et al
    Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL-1beta drives amplified responses in primed astrocytes and neuronal network dysfunction.
    Alzheimers Dement. 2021 Jun 3. doi: 10.1002/alz.12341.
    PubMed     Abstract available

  302. TEMP AGM, Lutz MW, Trepel D, Tang Y, et al
    How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease.
    Alzheimers Dement. 2021;17:917-919.

  303. FRANZMEIER N, Ossenkoppele R, Brendel M, Rubinski A, et al
    The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Abeta-associated tau accumulation and cognitive decline.
    Alzheimers Dement. 2021 Jun 1. doi: 10.1002/alz.12371.
    PubMed     Abstract available

  304. RICHARD E, den Brok MGHE, van Gool WA
    Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease.
    Alzheimers Dement. 2021;17:1051-1055.
    PubMed     Abstract available

  305. DE ERAUSQUIN GA, Snyder H, Carrillo M, Hosseini AA, et al
    The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning.
    Alzheimers Dement. 2021;17:1056-1065.
    PubMed     Abstract available

    May 2021
  306. SEXTON CE, Anstey KJ, Baldacci F, Barnum CJ, et al
    Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12380.
    PubMed     Abstract available

  307. O'BRYANT SE, Zhang F, Petersen M, Hall JR, et al
    A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12382.
    PubMed     Abstract available

    Beta-amyloid pore linked to controlled calcium influx into the cell: A new paradigm for Alzheimer's Disease.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12373.
    PubMed     Abstract available

  309. SCHWAHN C, Frenzel S, Holtfreter B, Van der Auwera S, et al
    Effect of periodontal treatment on preclinical Alzheimer's disease-Results of a trial emulation approach.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12378.
    PubMed     Abstract available

  310. RAJAN KB, Weuve J, Barnes LL, McAninch EA, et al
    Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060).
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12362.
    PubMed     Abstract available

  311. HAMPEL H, Shaw LM, Aisen P, Chen C, et al
    State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease.
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12372.
    PubMed     Abstract available

  312. JIANG Y, Zhou X, Ip FC, Chan P, et al
    Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.
    Alzheimers Dement. 2021 May 25. doi: 10.1002/alz.12369.
    PubMed     Abstract available

  313. APOSTOLOVA LG, Aisen P, Eloyan A, Fagan A, et al
    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology.
    Alzheimers Dement. 2021 May 21. doi: 10.1002/alz.12350.
    PubMed     Abstract available

  314. STERN Y, Stallard E, Kinosian B, Zhu C, et al
    Validation and demonstration of a new comprehensive model of Alzheimer's disease progression.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12336.
    PubMed     Abstract available

  315. HONG S, Dobricic V, Ohlei O, Bos I, et al
    TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12330.
    PubMed     Abstract available

  316. LIBIGER O, Shaw LM, Watson MH, Nairn AC, et al
    Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12353.
    PubMed     Abstract available

  317. GUSTAVSSON A, Raket LL, Lilja M, Rutten-Jacobs L, et al
    Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12355.
    PubMed     Abstract available

  318. MORGAN DG, Mielke MM
    Knowledge gaps in Alzheimer's disease immune biomarker research.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12342.
    PubMed     Abstract available

  319. OSSENKOPPELE R, Hansson O
    Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12356.
    PubMed     Abstract available

  320. MADRASI K, Das R, Mohmmadabdul H, Lin L, et al
    Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease.
    Alzheimers Dement. 2021 May 2. doi: 10.1002/alz.12312.
    PubMed     Abstract available

  321. Association commits $14 million to novel drug trials in rare form of Alzheimer's.
    Alzheimers Dement. 2021;17:910.

  322. STANLEY J, Howlett SE, Dunn T, Rockwood K, et al
    The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
    Alzheimers Dement. 2021;17:856-865.
    PubMed     Abstract available

  323. MIELKE MM, Przybelski SA, Lesnick TG, Kern S, et al
    Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
    Alzheimers Dement. 2021;17:801-812.
    PubMed     Abstract available

  324. WOODWORTH DC, Nguyen HL, Khan Z, Kawas CH, et al
    Utility of MRI in the identification of hippocampal sclerosis of aging.
    Alzheimers Dement. 2021;17:847-855.
    PubMed     Abstract available

  325. COUSINS KAQ, Phillips JS, Irwin DJ, Lee EB, et al
    ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.
    Alzheimers Dement. 2021;17:822-830.
    PubMed     Abstract available

    April 2021
  326. RANASINGHE KG, Petersen C, Kudo K, Mizuiri D, et al
    Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 21. doi: 10.1002/alz.12349.
    PubMed     Abstract available

  327. LI X, Tsolis KC, Koper MJ, Ronisz A, et al
    Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 19. doi: 10.1002/alz.12345.
    PubMed     Abstract available

  328. BABILONI C, Arakaki X, Azami H, Bennys K, et al
    Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.
    Alzheimers Dement. 2021 Apr 15. doi: 10.1002/alz.12311.
    PubMed     Abstract available

  329. MOELLER S, Sridhar J, Martersteck A, Coventry C, et al
    Functional decline in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 8. doi: 10.1002/alz.12331.
    PubMed     Abstract available

  330. MOLONEY CM, Lowe VJ, Murray ME
    Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12321.
    PubMed     Abstract available

  331. PROKOPENKO D, Morgan SL, Mullin K, Hofmann O, et al
    Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12319.
    PubMed     Abstract available

  332. SABBAGH MN, Cummings J
    Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".
    Alzheimers Dement. 2021;17:702-703.

  333. KULLER LH, Lopez OL
    ENGAGE and EMERGE: Truth and consequences?
    Alzheimers Dement. 2021;17:692-695.
    PubMed     Abstract available

  334. BRAY MJC, Richey LN, Bryant BR, Krieg A, et al
    Traumatic brain injury alters neuropsychiatric symptomatology in all-cause dementia.
    Alzheimers Dement. 2021;17:686-691.
    PubMed     Abstract available

  335. PLANCHE V, Bouteloup V, Mangin JF, Dubois B, et al
    Clinical relevance of brain atrophy subtypes categorization in memory clinics.
    Alzheimers Dement. 2021;17:641-652.
    PubMed     Abstract available

  336. STAFFARONI AM, Asken BM, Casaletto KB, Fonseca C, et al
    Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF).
    Alzheimers Dement. 2021;17:574-583.
    PubMed     Abstract available

  337. KNOPMAN DS, Jones DT, Greicius MD
    Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
    Alzheimers Dement. 2021;17:696-701.
    PubMed     Abstract available

    March 2021
  338. CHONG JR, Ashton NJ, Karikari TK, Tanaka T, et al
    Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12332.
    PubMed     Abstract available

  339. SHI L, Winchester LM, Westwood S, Baird AL, et al
    Replication study of plasma proteins relating to Alzheimer's pathology.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12322.
    PubMed     Abstract available

  340. HANSSON O, Batrla R, Brix B, Carrillo MC, et al
    The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12316.
    PubMed     Abstract available

  341. Register for May AAIC(R) Satellite Symposium and second Latinos & Alzheimer's symposium.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12337.

  342. AKHTER-KHAN SC, Tao Q, Ang TFA, Itchapurapu IS, et al
    Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study.
    Alzheimers Dement. 2021 Mar 24. doi: 10.1002/alz.12327.
    PubMed     Abstract available

  343. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2021 Mar 23. doi: 10.1002/alz.12328.
    PubMed     Abstract available

  344. BECKMAN D, Chakrabarty P, Ott S, Dao A, et al
    A novel tau-based rhesus monkey model of Alzheimer's pathogenesis.
    Alzheimers Dement. 2021 Mar 18. doi: 10.1002/alz.12318.
    PubMed     Abstract available

  345. KOCIOLEK AJ, Fernandez KK, Jin Z, Cosentino S, et al
    Extrapyramidal signs and Alzheimer's disease prognosis in a multiethnic, community-based sample of demented elders.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12309.
    PubMed     Abstract available

  346. DISBROW E, Stokes KY, Ledbetter C, Patterson J, et al
    Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12305.
    PubMed     Abstract available

  347. FALGAS N, Walsh CM, Neylan TC, Grinberg LT, et al
    Deepen into sleep and wake patterns across Alzheimer's disease phenotypes.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12304.
    PubMed     Abstract available

  348. RAHMAN M, White EM, Mills C, Thomas KS, et al
    Rural-urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12285.
    PubMed     Abstract available

  349. SALVADO G, Mila-Aloma M, Shekari M, Minguillon C, et al
    Cerebral amyloid-beta load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12245.
    PubMed     Abstract available

  350. TURNER DA, Degan S, Hoffmann U, Galeffi F, et al
    CVN-AD Alzheimer's mice show premature reduction in neurovascular coupling in response to spreading depression and anoxia compared to aged controls.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12289.
    PubMed     Abstract available

  351. MASEREJIAN N, Krzywy H, Eaton S, Galvin JE, et al
    Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12280.
    PubMed     Abstract available

  352. SAITO ER, Miller JB, Harari O, Cruchaga C, et al
    Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression.
    Alzheimers Dement. 2021 Mar 2. doi: 10.1002/alz.12310.
    PubMed     Abstract available

  353. LI Y, Xiong C, Aschenbrenner AJ, Chang CH, et al
    Item response theory analysis of the Clinical Dementia Rating.
    Alzheimers Dement. 2021;17:534-542.
    PubMed     Abstract available

  354. FANI L, Ahmad S, Ikram MK, Ghanbari M, et al
    Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study.
    Alzheimers Dement. 2021;17:446-456.
    PubMed     Abstract available

  355. GRANOT-HERSHKOVITZ E, Tarraf W, Kurniansyah N, Daviglus M, et al
    APOE alleles' association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL).
    Alzheimers Dement. 2021;17:466-474.
    PubMed     Abstract available

    February 2021
  356. ASHFORD MT, Veitch DP, Neuhaus J, Nosheny RL, et al
    The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12253.
    PubMed     Abstract available

  357. BRICKMAN AM, Manly JJ, Honig LS, Sanchez D, et al
    Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12301.
    PubMed     Abstract available

  358. IZZO NJ, Yuede CM, LaBarbera KM, Limegrover CS, et al
    Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Alzheimers Dement. 2021 Feb 8. doi: 10.1002/alz.12302.
    PubMed     Abstract available

  359. BLEILE L
    Alzheimer's Association Update.
    Alzheimers Dement. 2021 Feb 4. doi: 10.1002/alz.12306.

  360. WANG R, Qiu C, Dintica CS, Shang Y, et al
    Shared risk and protective factors between Alzheimer's disease and ischemic stroke: A population-based longitudinal study.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12203.
    PubMed     Abstract available

  361. GUZMAN-VELEZ E, Zetterberg H, Fox-Fuller JT, Vila-Castelar C, et al
    Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12248.
    PubMed     Abstract available

  362. GRISWOLD AJ, Celis K, Bussies PL, Rajabli F, et al
    Increased APOE epsilon4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12287.
    PubMed     Abstract available

  363. HAGHANI A, Thorwald M, Morgan TE, Finch CE, et al
    The APOE gene cluster responds to air pollution factors in mice with coordinated expression of genes that differs by age in humans.
    Alzheimers Dement. 2021;17:175-190.
    PubMed     Abstract available

  364. CHEN XQ, Salehi A, Pearn ML, Overk C, et al
    Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Alzheimers Dement. 2021;17:271-292.
    PubMed     Abstract available

  365. BLUE EE, Thornton TA, Kooperberg C, Liu S, et al
    Non-coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women.
    Alzheimers Dement. 2021;17:215-225.
    PubMed     Abstract available

  366. DE LEEUW FA, Karamujic-Comic H, Tijms BM, Peeters CFW, et al
    Circulating metabolites are associated with brain atrophy and white matter hyperintensities.
    Alzheimers Dement. 2021;17:205-214.
    PubMed     Abstract available

    January 2021
  367. AYTON S, Portbury S, Kalinowski P, Agarwal P, et al
    Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12282.
    PubMed     Abstract available

  368. SIMREN J, Leuzy A, Karikari TK, Hye A, et al
    The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12283.
    PubMed     Abstract available

  369. GERMANN J, Elias GJB, Boutet A, Narang K, et al
    Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12238.
    PubMed     Abstract available

  370. BRYAN J, Mandan A, Kamat G, Gottschalk WK, et al
    Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12223.
    PubMed     Abstract available

  371. LUCKETT PH, McCullough A, Gordon BA, Strain J, et al
    Modeling autosomal dominant Alzheimer's disease with machine learning.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12259.
    PubMed     Abstract available

  372. LI HD, Funk CC, McFarland K, Dammer EB, et al
    Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12254.
    PubMed     Abstract available

  373. Alzheimer's Association International Conference Neuroscience Next focused on early career researchers across all of neuroscience.
    Alzheimers Dement. 2021;17:138-139.

  374. CHIARI A, Vinceti G, Adani G, Tondelli M, et al
    Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy.
    Alzheimers Dement. 2021;17:81-88.
    PubMed     Abstract available

    December 2020
  375. VAN HULLE C, Jonaitis EM, Betthauser TJ, Batrla R, et al
    An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.
    Alzheimers Dement. 2020 Dec 18. doi: 10.1002/alz.12204.
    PubMed     Abstract available

  376. LYSSENKO NN, Pratico D
    ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 17. doi: 10.1002/alz.12220.
    PubMed     Abstract available

    Recognizing African-American contributions to neurology: The role of Solomon Carter Fuller (1872-1953) in Alzheimer's disease research.
    Alzheimers Dement. 2020 Dec 15. doi: 10.1002/alz.12183.
    PubMed     Abstract available

  378. AUDRAIN M, Haure-Mirande JV, Mleczko J, Wang M, et al
    Reactive or transgenic increase in microglial TYROBP reveals a TREM2-independent TYROBP-APOE link in wild-type and Alzheimer's-related mice.
    Alzheimers Dement. 2020 Dec 12. doi: 10.1002/alz.12256.
    PubMed     Abstract available

  379. KIM YW, Al-Ramahi I, Koire A, Wilson SJ, et al
    Harnessing the paradoxical phenotypes of APOE varepsilon2 and APOE varepsilon4 to identify genetic modifiers in Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 7. doi: 10.1002/alz.12240.
    PubMed     Abstract available

  380. FRYE BM, Craft S, Register TC, Andrews RN, et al
    Diet, psychosocial stress, and Alzheimer's disease-related neuroanatomy in female nonhuman primates.
    Alzheimers Dement. 2020 Dec 3. doi: 10.1002/alz.12232.
    PubMed     Abstract available

    November 2020
  381. KARIKARI TK, Emersic A, Vrillon A, Lantero-Rodriguez J, et al
    Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
    Alzheimers Dement. 2020 Nov 30. doi: 10.1002/alz.12236.
    PubMed     Abstract available

  382. LLIBRE-GUERRA JJ, Li Y, Allegri RF, Mendez PC, et al
    Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12227.
    PubMed     Abstract available

  383. DUENAS MR, Snyder PJ
    Alzheimer's team care approach-akin to diabetes-in the development, validation, and population assessment of retinal biomarkers for disease.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12234.
    PubMed     Abstract available

  384. SPENCER BE, Digma LA, Jennings RG, Brewer JB, et al
    Gene- and age-informed screening for preclinical Alzheimer's disease trials.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12207.
    PubMed     Abstract available

  385. HITHERSAY R, Baksh RA, Startin CM, Wijeratne P, et al
    Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12222.
    PubMed     Abstract available

  386. PENTZ R, Iulita MF, Ducatenzeiler A, Videla L, et al
    Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12229.
    PubMed     Abstract available

  387. MONTAL V, Vilaplana E, Pegueroles J, Bejanin A, et al
    Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2020 Nov 16. doi: 10.1002/alz.12224.
    PubMed     Abstract available

  388. JESSEN F, Kleineidam L, Wolfsgruber S, Bickel H, et al
    Prediction of dementia of Alzheimer type by different types of subjective cognitive decline.
    Alzheimers Dement. 2020 Nov 2. doi: 10.1002/alz.12163.
    PubMed     Abstract available

  389. Alzheimer's Association pays tribute to former Chief Science Officer William (Bill) Thies, PhD.
    Alzheimers Dement. 2020;16:1600-1605.

    October 2020
  390. SOHEILI-NEZHAD S, van der Linden RJ, Olde Rikkert M, Sprooten E, et al
    Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiology.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12211.
    PubMed     Abstract available

  391. ARNSTEN AFT, Datta D, Tredici KD, Braak H, et al
    Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12192.
    PubMed     Abstract available

  392. WESSELS AM, Lines C, Stern RA, Kost J, et al
    Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 13. doi: 10.1002/alz.12164.
    PubMed     Abstract available

  393. MECCA AP, van Dyck CH
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
    Alzheimers Dement. 2020 Oct 12. doi: 10.1002/alz.12190.

  394. SNYDER PJ, Alber J, Alt C, Bain LJ, et al
    Retinal imaging in Alzheimer's and neurodegenerative diseases.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12179.
    PubMed     Abstract available

  395. THUNELL J, Chen Y, Joyce G, Barthold D, et al
    Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12175.
    PubMed     Abstract available

  396. JAIN S, Rosenbaum PR, Reiter JG, Hoffman G, et al
    Using Medicare claims in identifying Alzheimer's disease and related dementias.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12199.
    PubMed     Abstract available

  397. HOU X, Watzlawik JO, Cook C, Liu CC, et al
    Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12198.
    PubMed     Abstract available

  398. BUBU OM, Umasabor-Bubu OQ, Turner AD, Parekh A, et al
    Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12184.
    PubMed     Abstract available

    August 2020
  399. DENNY A, Streitz M, Stock K, Balls-Berry JE, et al
    Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018.
    Alzheimers Dement. 2020 Aug 17. doi: 10.1002/alz.12160.
    PubMed     Abstract available

    April 2020
  400. CABALLERO MAA, Song Z, Rubinski A, Duering M, et al
    Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span.
    Alzheimers Dement. 2020;16:651-661.
    PubMed     Abstract available

    March 2020
  401. LOWE VJ, Lundt ES, Albertson SM, Min HK, et al
    Tau-positron emission tomography correlates with neuropathology findings.
    Alzheimers Dement. 2020;16:561-571.
    PubMed     Abstract available

  402. PAPP KV, Buckley R, Mormino E, Maruff P, et al
    Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.
    Alzheimers Dement. 2020;16:552-560.
    PubMed     Abstract available

    February 2020
  403. ANTONELL A, Tort-Merino A, Rios J, Balasa M, et al
    Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
    Alzheimers Dement. 2020;16:262-272.
    PubMed     Abstract available

  404. ANGULO SL, Henzi T, Neymotin SA, Suarez MD, et al
    Amyloid pathology-produced unexpected modifications of calcium homeostasis in hippocampal subicular dendrites.
    Alzheimers Dement. 2020;16:251-261.
    PubMed     Abstract available

    January 2020
  405. KAPLOW J, Vandijck M, Gray J, Kanekiyo M, et al
    Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status.
    Alzheimers Dement. 2020;16:144-152.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.